Drugs / Multivitamins
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00383409 | Mar → Aug 2006 | breast cancer | Faculdade de Medicina do ABC | Completed | No outcome recorded |
| Phase 32 trials · 1 missed | ||||||
| Phase 3 | NCT00421668 | Sep 2007 → Oct 2012 | diarrheal disease, respiratory tract infectious disorder | Harvard School of Public Health (HSPH) | Completed | No outcome recorded |
| Phase 3 | NCT00197730 | Jun 2004 → May 2008 | HIV infectious disease, pregnancy disorder | Harvard School of Public Health (HSPH) | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00034463 Background | — | cancer, metastatic neoplasm | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | multivitamins | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00383409 ↗ |
| Known as | MVi | “Multivitamins (MVi) are broadly used by cancer patients to improve overall health and energy.” NCT00383409 ↗ |
| Known as | MVs | “randomly assigned to receive daily oral supplementation of MVs (vitamin B complex and vitamins C and E), zinc, zinc + MVs, or placebo for 18 mo.” PMID 26203094 ↗ Jul 2015 |
| Route | Oral | “administered orally to children aged 6 weeks” NCT00197730 ↗ |